SCEL expression in tumor tissues: A potential prognostic biomarker for recurrent papillary thyroid carcinoma.
Аннотация
BACKGROUND
Although papillary thyroid carcinoma (PTC) generally has a favorable prognosis, recurrence occurs in a significant number of patients, and its underlying mechanisms remain incompletely understood. This study investigated the prognostic significance of SCEL expression in recurrent PTC.
METHODS
SCEL expression was analyzed in PTC and normal tissues using GEPIA and TIMER2.0 databases, with validation by immunohistochemistry (IHC) in clinical samples. SCEL levels were compared between recurrent PTC (n = 50), non-recurrent PTC (n = 150), and tissues using Mann-Whitney U tests. Associations with clinicopathological features were assessed. Kaplan-Meier (log-rank) and Cox regression analyses evaluated survival outcomes. Relationships between SCEL, epithelial-mesenchymal transition (EMT), and immune cell infiltration were investigated using TIMER2.0, IHC, and correlation analysis.
RESULTS
Significantly elevated SCEL expression in PTC tissues versus normal controls (P < 0.01). Higher SCEL levels in recurrent PTC versus non-recurrent PTC (P < 0.01), correlating with increased recurrence risk. SCEL expression levels were significantly correlated with TNM stage, AJCC stage, and I-131 treatment status (P < 0.01). Lower SCEL expression predicted significantly improved prognosis in recurrent PTC patients. Multivariate Cox analysis confirmed low SCEL as an independent protective factor for disease-free survival (DFS) (HR = 0.358, 95 % CI: 0.149-0.861, P = 0.022). Recurrence showed no significant association with EMT pathways. This prognostic advantage was mechanistically linked to enhanced tumor immune cell infiltration in the low-SCEL group (P < 0.01), whereas high SCEL correlated with an immunosuppressive microenvironment.
CONCLUSIONS
This study identifies SCEL as a recurrence-associated potential biomarker in PTC. Critically, lower SCEL expression may serve as a potential independent protective factor, predicting improved DFS in recurrent PTC patients. This survival benefit is mediated through modulation of the tumor immune microenvironment rather than EMT pathways.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.